https://orcid.org/0000-0002-6036-7133
References
- Martins AC, Rosa AM, Costa E, et al. Ocular manifestations and therapeutic options in patients with familial amyloid polyneuropathy: a systematic review. Biomed Res Int. 2015;2015:282405.
- Klein CJ, Nakumura M, Jacobson DR, et al. Transthyretin amyloidosis (serine 44) with headache, hearing loss, and peripheral neuropathy. Neurology. 1998;51(5):1462–1464.
- Lim A, Prokaeva T, McComb ME, et al. Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis. Anal Chem. 2002;74(4):741–751.
- Murakami A, Fujiki K, Hasegawa S, et al. Transthyretin ser-44 mutation in a case with vitreous amyloidosis. Am J Ophthalmol. 2002;133(2):272–273.
- Lemos C, Coelho T, Alves-Ferreira M, et al. Overcoming artefact: anticipation in 284 portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry. 2014;85(3):326–330.